Silexion Therapeutics (SLXN) Directors and Executive Officers

Officers & Directors

As of December 31, 2025, the executive officers are Ilan Hadar, Chairman and Chief Executive Officer, formerly Managing Director of Silexion Israel; Mirit Horenshtein Hadar, Chief Financial Officer and Secretary, formerly Executive Vice President of Finance at Silexion Israel; and Dr. Mitchell Shirvan, Chief Scientific and Development Officer, formerly holding the same position at Silexion Israel. Prior to the Business Combination in August 2024, Mr. Hadar served part-time at 75% capacity and full-time thereafter. Dr. Shirvan served part-time at 80% capacity before the Business Combination and full-time thereafter. Their base salaries for 2025 were $382,398 for Mr. Hadar, $250,297 for Ms. Horenshtein Hadar, and $278,108 for Dr. Shirvan. Additional compensation included payments for leased cars, pension contributions, and continuing education funds. No new equity compensation was granted in 2025.

Silexion Therapeutics Corp currently has 14 employees.

News about Silexion Therapeutics Corp Key Personnel

Silexion Therapeutics: Pioneering a New Era in Cancer Treatment with Strategic Leadership and Regulatory Compliance

In the fast-paced world of biotechnology, Silexion Therapeutics has recently made significant strides that could redefine its trajectory in cancer treatment. The dual announcement of a new board member and a strategic stock split underscores the company’s commitment to innovation, growth, and regulatory compliance—crucial elements in the highly competitive biotech landscape. New Leadership in the Fight Against CancerSilexion Therapeutics has appointed Professor Amnon Peled to its Board of Directors. A globally recognized authority in cancer therapeutics, Prof. Peled brings a wealth of experience from his involvement with multiple successful publicly traded biopharma companies. His expertise primarily lie...